|
Mon, 12/03/2018 - 05:15 |
The Senate Must Reject Poison Pill Amendments to the First Step Act |
FreedomWorks |
|
Sun, 12/02/2018 - 10:54 |
Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID In Combination with Rituximab (R) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018 |
BMS |
|
Sun, 08/19/2018 - 22:51 |
China National Drug Administration grants rapid approval of Roches Alecensa (alectinib) as a treatment for ALK-positive lung cancer |
Rocheusa |
|
Wed, 05/16/2018 - 20:22 |
Follow-up phase III data showed Roches Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death |
Rocheusa |
|
Wed, 05/16/2018 - 15:22 |
Follow-Up Phase III Data Showed Genentechs Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death |
Genentech |
|
Wed, 12/20/2017 - 22:41 |
European Commission approves Roches Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer |
Rocheusa |
|
Tue, 10/31/2017 - 14:23 |
US FDA approves AstraZenecas Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma |
AstraZeneca |
|
Fri, 10/13/2017 - 04:56 |
CHMP recommends EU approval of Roches Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC |
Rocheusa |
|
Wed, 08/02/2017 - 00:42 |
FDA Grants Genentechs Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer |
Genentech |
|
Wed, 04/12/2017 - 06:27 |
RBC Global Asset Management announces changes to RBC Advisor Canadian Bond Fund |
Royal Bank Of Canada |
|
Mon, 04/10/2017 - 03:11 |
Met Its Primary Endpoint in the ALEX Study |
Chugai |
|
Wed, 03/29/2017 - 22:36 |
Phase III study shows Roches Alecensa was superior to crizotinib in a specific type of lung cancer |
Rocheusa |
|
Mon, 02/27/2017 - 02:45 |
Chugais ALK Inhibitor Alecensa |
Chugai |
|
Tue, 02/21/2017 - 02:28 |
- Alecensa is Available Now in Japan, the United States and Europe - |
Chugai |
|
Thu, 01/19/2017 - 06:43 |
IMBRUVICA (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy |
Johnson and Johnson |
|
Mon, 12/05/2016 - 12:02 |
New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkins Lymphoma |
Johnson and Johnson |
|
Mon, 09/26/2016 - 08:32 |
Ibrutinib (IMBRUVICA ) Supplemental New Drug Application Submitted to the U.S. Food and Drug Administration (FDA) for Marginal Zone Lymphoma (MZL) |
Johnson and Johnson |
